Results 71 to 80 of about 40,773 (330)
Cardiovascular Diabetology, 2022 Background The Food and Drug Administration has approved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia.
Xing Wang +4 more
semanticscholar +1 more source
The Role of PCSK9 in Infectious Diseases
Current Medicinal Chemistry, 2022 Background: In recent years, many aspects of the physiological role of PCSK9 have been elucidated, in particular regarding its role in lipid metabolism, cardiovascular risk but also its role in innate immunity. Increasing evidence is available on the involvement of PCSK9 in the pathogenesis of viral infections, mainly HCV, as well as in the regulation
Magnasco, Laura +7 more
openaire +3 more sources
JCI Insight, 2022 Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
Alexander Merleev +19 more
doaj +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
JAMA cardiology, 2022 Importance Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density lipoprotein cholesterol (LDL-C).
A. Cupido +6 more
semanticscholar +1 more source
PCSK9 inhibitors for hypercholesterolaemia [PDF]
BMJ, 2017 New drugs, old problems Statins (hydroxymethyl-glutaryl coenzyme A reductase inhibitors) reduce “bad” low density lipoprotein (LDL) cholesterol concentrations and cardiovascular risk. So too, do better diet and more exercise, which together almost halve rates of coronary event rates when compared with an “unfavourable lifestyle.”3 For some people ...
Robin E Ferner, Patricia McGettigan
openaire +2 more sources
Glycaemic effects of non-statin lipid-lowering therapies [PDF]
, 2016 Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for ...
Collins, Patrick D., Sattar, Naveed
core +1 more source
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
Circulation, 2019 Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration.
M. O’Donoghue +19 more
semanticscholar +1 more source
PCSK9 and cancer: Rethinking the link
Biomedicine & Pharmacotherapy, 2021 Cancer is emerging as a major problem globally, as it accounts for the second cause of death despite medical advances. According to epidemiological and basic studies, cholesterol is involved in cancer progression and there are abnormalities in cholesterol metabolism of cancer cells including prostate, breast, and colorectal carcinomas.
Mahboobnia K. +6 more
openaire +4 more sources
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD) [PDF]
Advanced Pharmaceutical Bulletin, 2020 Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage.
Saeideh Sobati +6 more
doaj +1 more source